Resveratrol

Resveratrol carries enough safety and interaction concerns that most healthy adults should treat it as a low-priority experiment rather than a core supplement. The evidence base shows no consistent activation of the touted SIRT1 pathway across eleven randomized trials, limiting any broad metabolic claim Mansouri 2025. Moreover, oral bioavailability remains modest and highly variable, meaning that even milligram doses translate to only trace circulating levels, which complicates dose-response expectations Szymkowiak 2025. High-dose oncology studies have revealed acute renal injury and rare fatalities, underscoring a steep risk curve that does not apply to typical 150-500 mg daily regimens but warns against unchecked escalation. Regular users also face notable drug-interaction potential with anticoagulants and statins, and the modest cognitive or lipid signals observed in post-menopausal cohorts do not offset these drawbacks. Consequently, individuals with stable health profiles, limited polypharmacy, and modest budget constraints may opt to skip Resveratrol until clearer benefit data emerge.

Safety risk (4.0/5.0). Resveratrol's worst-case safety risk is high enough to dominate the downside score. Popat 2013 reported acute renal failure in 5 of 24 relapsed or refractory multiple-myeloma patients using 5 g/day SRT501 plus bortezomib, including one death and trial termination. That was a high-dose oncology context, not standard 150-500 mg supplement use, but it proves resveratrol is not risk-free at pharmacologic exposure. Andreani 2017 adds hormone-sensitive oncology caution. Low-dose users mainly face interaction screening, but the severe edge cases are real.

Side effect profile (3.0/5.0). Resveratrol has a meaningful mild-to-moderate side-effect tail. GI upset, nausea, diarrhea, abdominal cramping, and headache are the common practical complaints, especially as dosing rises above 1 g/day. Knotweed-derived products add emodin-quality concerns. Drug interactions matter more than routine symptoms: CYP2C9 inhibition can affect warfarin, BCRP inhibition can affect rosuvastatin and topotecan, and antiplatelet stacking can increase bleeding concern. Compared with creatine or omega-3, resveratrol has more interaction complexity and less upside to justify casual use.

Financial cost (1.5/5.0). Resveratrol is cheap. Generic trans-resveratrol usually costs about $15-30 per month at common supplemental doses, while premium third-party-tested versions often land around $35-50 per month. The low cost prevents the score from falling further despite weak efficacy. The practical financial warning is quality control, not sticker price: under-dosed products, knotweed contaminants, and vague standardization can turn a cheap experiment into noisy self-tracking. Synthetic trans-resveratrol or reputable third-party-tested products are the cleaner choice if someone still wants a trial.

Time / effort burden (1.0/5.0). Resveratrol requires almost no effort. The default protocol is swallowing one capsule once or twice daily, usually with food. There is no device setup, training block, calendar scheduling, app tracking, or travel friction. Monitoring only becomes effortful when the user has polypharmacy, anticoagulant use, renal disease, hormone-sensitive cancer history, or a high-dose plan. For a healthy low-dose user, the day-to-day effort burden is the minimum possible for a supplement. That low effort is one reason resveratrol stayed popular despite the weak longevity evidence.

Opportunity cost (3.5/5.0). Resveratrol has a real opportunity-cost problem because it competes with better-supported longevity and cardiometabolic interventions. Gliemann 2013 is the practical warning: 250 mg/day resveratrol blunted several cardiovascular adaptations to exercise training in older men. Exercise is more important than resveratrol, so even a moderate chance of interference matters. Resveratrol also displaces higher-confidence options such as blood-pressure control, lipid management, omega-3, berberine, urolithin A, sleep, and structured training.

Dependency / withdrawal (1.5/5.0). Resveratrol has no addiction, craving, withdrawal syndrome, receptor-dependence pattern, or known rebound below baseline. Stopping should simply remove whatever small concentration-dependent effect the user was getting. The score is 1.5 rather than 1.0 because a narrow group may experience loss of subtle vascular, glycemic, or cognitive support after discontinuation, similar to stopping any weakly active supplement. There is no physiological reason to taper. The main discontinuation issue is psychological attachment to the longevity narrative, not pharmacology.

Reversibility (1.5/5.0). Resveratrol's ordinary pharmacologic effects are reversible, but a narrow safety caveat prevents a perfect reversibility score. For most users, stopping resveratrol should end exposure within days as parent compound and conjugates clear. No structural tissue change or permanent receptor adaptation is expected. The caveat is severe-context harm: acute renal failure in Popat 2013 and hormone-sensitive tumor-promotion concern in Andreani 2017 are not consequences you can assume reverse cleanly once triggered. General-user reversibility is high; edge-case reversibility is not.